IL293140A - Vector variants of adenoviruses - Google Patents
Vector variants of adenovirusesInfo
- Publication number
- IL293140A IL293140A IL293140A IL29314022A IL293140A IL 293140 A IL293140 A IL 293140A IL 293140 A IL293140 A IL 293140A IL 29314022 A IL29314022 A IL 29314022A IL 293140 A IL293140 A IL 293140A
- Authority
- IL
- Israel
- Prior art keywords
- capsid protein
- modified
- seq
- aav capsid
- targeting peptide
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14145—Special targeting system for viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14171—Demonstrated in vivo effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Virology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962939315P | 2019-11-22 | 2019-11-22 | |
| US202063084709P | 2020-09-29 | 2020-09-29 | |
| PCT/US2020/061464 WO2021102234A1 (en) | 2019-11-22 | 2020-11-20 | Adeno-associated viral vector variants |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL293140A true IL293140A (en) | 2022-07-01 |
Family
ID=75980202
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL293140A IL293140A (en) | 2019-11-22 | 2020-11-20 | Vector variants of adenoviruses |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US12653910B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4061427A4 (cg-RX-API-DMAC7.html) |
| JP (3) | JP7712271B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102997604B1 (cg-RX-API-DMAC7.html) |
| CN (2) | CN115023242B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020388404A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022009864A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3159113A1 (cg-RX-API-DMAC7.html) |
| CO (1) | CO2022008507A2 (cg-RX-API-DMAC7.html) |
| IL (1) | IL293140A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022006188A (cg-RX-API-DMAC7.html) |
| PH (1) | PH12022551247A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021102234A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL297237B2 (en) * | 2020-04-17 | 2025-08-01 | Regeneron Pharma | Detection assays for coronavirus neutralizing antibodies |
| KR20240095539A (ko) | 2021-10-08 | 2024-06-25 | 디노 테라퓨틱스, 인코포레이티드 | 캡시드 변이체 및 이의 사용 방법 |
| JP2025514794A (ja) * | 2022-04-22 | 2025-05-09 | ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィア | ヒト上衣特異的プロモーターおよびその使用方法 |
| EP4522272A4 (en) * | 2022-05-11 | 2026-07-29 | Childrens Hospital Philadelphia | Adeno-associated viral vectors to target deep brain structures |
| JP2025516715A (ja) * | 2022-05-13 | 2025-05-30 | ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィア | 脳微小血管系を標的とするアデノ随伴ウイルスベクター |
| CN119213120A (zh) | 2022-05-16 | 2024-12-27 | 建新公司 | 治疗异染性脑白质营养不良的方法 |
| WO2024017387A1 (en) * | 2022-07-22 | 2024-01-25 | Shanghai Vitalgen Biopharma Co., Ltd. | Novel aav capsids for targeting nervous system and uses thereof |
| KR102870168B1 (ko) * | 2022-08-26 | 2025-10-13 | 김선아 | 활막 표적화 화합물 및 이의 용도 |
| CN120187459A (zh) * | 2022-09-19 | 2025-06-20 | 费城儿童医院 | 使用split-seq在单细胞分辨率下的aav进化 |
| IL322459A (en) * | 2023-01-31 | 2025-09-01 | Childrens Hospital Philadelphia | Innovative gene therapy construct for cln2 disease |
| JP2026509271A (ja) | 2023-03-10 | 2026-03-17 | ダイノ セラピューティクス,インコーポレーテッド | カプシドポリペプチドおよびその使用方法 |
| CN117964715B (zh) * | 2023-07-21 | 2025-01-24 | 广州派真生物技术有限公司 | 腺相关病毒突变体及其应用 |
| KR20260082361A (ko) | 2023-08-31 | 2026-06-04 | 디노 테라퓨틱스, 인코포레이티드 | 캡시드 폴리펩타이드 및 이의 사용 방법 |
| WO2025090631A1 (en) * | 2023-10-23 | 2025-05-01 | The Children's Hospital Of Philadelphia | Aav vectors for delivery of apoe2 |
| CN122319003A (zh) * | 2023-10-23 | 2026-06-30 | 费城儿童医院 | 用于治疗cln2疾病的aav载体 |
| AR134407A1 (es) * | 2023-11-15 | 2026-01-14 | Genzyme Corp | Métodos de tratamiento de la enfermedad de gaucher y de la enfermedad de parkinson gba |
| CN122206466A (zh) * | 2023-11-15 | 2026-06-12 | 建新公司 | 治疗神经变性障碍的方法 |
| TW202545971A (zh) | 2024-02-08 | 2025-12-01 | 美商戴諾治療公司 | 殼體多肽及其使用方法 |
| WO2025213097A1 (en) * | 2024-04-05 | 2025-10-09 | The Children's Hospital Of Philadelphia | Novel gene therapy constructs for stxbp1 haploinsufficiency |
| WO2025231406A1 (en) * | 2024-05-02 | 2025-11-06 | The Children's Hospital Of Philadelphia | Methods to increase transduction of ependyma cells in brain |
| WO2026052039A1 (en) * | 2024-09-06 | 2026-03-12 | Sichuan Real & Best Biotech Co., Ltd. | Engineered adeno-associated virus capsid protein and the use thereof |
| WO2026064442A2 (en) | 2024-09-18 | 2026-03-26 | Dyno Therapeutics, Inc. | Capsid polypeptides and methods of use thereof |
| WO2026122963A1 (en) | 2024-12-06 | 2026-06-11 | Dyno Therapeutics, Inc. | Capsid polypeptides and methods of use thereof |
| WO2026165267A1 (en) * | 2025-01-31 | 2026-08-06 | Genzyme Corporation | Methods of treating neurodegenerative disorders |
| CN121265801A (zh) * | 2025-06-06 | 2026-01-06 | 昆明理工大学 | 一种靶向性的药物递送载体及其制备方法 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040031072A1 (en) * | 1999-05-06 | 2004-02-12 | La Rosa Thomas J. | Soy nucleic acid molecules and other molecules associated with transcription plants and uses thereof for plant improvement |
| DK2359869T3 (en) | 2001-12-17 | 2019-04-15 | Univ Pennsylvania | Sequences of adeno-associated virus (AAV) serotype 8, vectors containing these, and uses thereof |
| WO2006105392A2 (en) | 2005-03-30 | 2006-10-05 | The Cleveland Clinic Foundation | Neuron targeting peptides |
| CA2693712C (en) | 2007-07-14 | 2018-05-29 | The University Of Iowa Research Foundation | Methods and compositions for treating brain diseases |
| WO2011119484A1 (en) | 2010-03-23 | 2011-09-29 | Iogenetics, Llc | Bioinformatic processes for determination of peptide binding |
| US10738326B2 (en) | 2010-10-27 | 2020-08-11 | Jichi Medical University | Adeno-associated virus vector for gene transfer to nervous system cells |
| EP3564379A1 (en) | 2013-09-13 | 2019-11-06 | California Institute of Technology | Selective recovery |
| DE102014207498A1 (de) * | 2014-04-17 | 2015-10-22 | Universitätsklinikum Hamburg-Eppendorf | Viraler Vektor für den zielgerichteten Gentransfer in Gehirn und Rückenmark |
| AU2015349759B2 (en) | 2014-11-21 | 2022-01-06 | The University Of North Carolina At Chapel Hill | Aav vectors targeted to the central nervous system |
| CA2977355A1 (en) | 2015-02-20 | 2016-08-25 | University Of Iowa Research Foundation | Methods and compositions for treating genetic eye diseases |
| AU2016366549B2 (en) | 2015-12-11 | 2022-11-10 | California Institute Of Technology | Targeting peptides for directing adeno-associated viruses (AAVs) |
| CN109640949B (zh) | 2016-07-29 | 2022-11-25 | 加利福尼亚大学董事会 | 具有变异衣壳的腺相关病毒病毒体和其使用方法 |
| EP3583220A4 (en) | 2017-02-15 | 2021-07-07 | The University of North Carolina at Chapel Hill | PROCEDURES AND COMPOSITIONS FOR GENERAL TRANSFER IN THE VASCULAR SYSTEM |
| MX2019013528A (es) * | 2017-05-12 | 2020-07-14 | The Children´S Hospital Of Philadelphia | Variantes de sulfamidasa (sgsh) y vectores, composiciones, metodos y usos para tratar la mucopolisacaridosis tipo iiia (mps iiia). |
| DK3684423T5 (da) * | 2017-09-20 | 2024-08-26 | 4D Molecular Therapeutics Inc | Adeno-associerede virusvariantcapsider og fremgangsmåder til anvendelse deraf |
| MX2020003042A (es) * | 2017-09-29 | 2020-11-18 | Voyager Therapeutics Inc | Rescate del fenotipo neurológico central y periférico de la ataxia de friedreich mediante administración intravenosa. |
| WO2019113538A2 (en) | 2017-12-07 | 2019-06-13 | California Institute Of Technology | Methods and systems for noninvasive control of brain cells and related vectors and compositions |
| WO2019222329A1 (en) | 2018-05-15 | 2019-11-21 | Voyager Therapeutics, Inc. | Compositions and methods for delivery of aav |
| JP2021530218A (ja) * | 2018-07-11 | 2021-11-11 | ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドThe Brigham and Women’s Hospital, Inc. | 血液脳関門を超える薬剤の送達のための方法および組成物 |
| CN115605596A (zh) | 2020-02-12 | 2023-01-13 | 费城儿童医院(Us) | 用于基因表达的诱导型可变剪接调节的组合物和方法 |
-
2020
- 2020-11-20 CN CN202080094086.2A patent/CN115023242B/zh active Active
- 2020-11-20 WO PCT/US2020/061464 patent/WO2021102234A1/en not_active Ceased
- 2020-11-20 KR KR1020227021143A patent/KR102997604B1/ko active Active
- 2020-11-20 MX MX2022006188A patent/MX2022006188A/es unknown
- 2020-11-20 EP EP20890214.8A patent/EP4061427A4/en active Pending
- 2020-11-20 CN CN202510215753.2A patent/CN119978146A/zh active Pending
- 2020-11-20 BR BR112022009864A patent/BR112022009864A2/pt unknown
- 2020-11-20 US US17/778,783 patent/US12653910B2/en active Active
- 2020-11-20 CA CA3159113A patent/CA3159113A1/en active Pending
- 2020-11-20 AU AU2020388404A patent/AU2020388404A1/en active Pending
- 2020-11-20 PH PH1/2022/551247A patent/PH12022551247A1/en unknown
- 2020-11-20 JP JP2022529681A patent/JP7712271B2/ja active Active
- 2020-11-20 IL IL293140A patent/IL293140A/en unknown
-
2022
- 2022-06-16 CO CONC2022/0008507A patent/CO2022008507A2/es unknown
-
2023
- 2023-10-20 US US18/491,365 patent/US20240100194A1/en active Pending
-
2025
- 2025-03-19 JP JP2025044678A patent/JP7888221B2/ja active Active
- 2025-07-10 JP JP2025116303A patent/JP2025148448A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20230346981A1 (en) | 2023-11-02 |
| JP7888221B2 (ja) | 2026-07-13 |
| US20240100194A1 (en) | 2024-03-28 |
| PH12022551247A1 (en) | 2023-11-13 |
| KR102997604B1 (ko) | 2026-07-29 |
| JP2023503455A (ja) | 2023-01-30 |
| JP2025148448A (ja) | 2025-10-07 |
| JP7712271B2 (ja) | 2025-07-23 |
| US12653910B2 (en) | 2026-06-16 |
| CN115023242A (zh) | 2022-09-06 |
| AU2020388404A1 (en) | 2022-06-09 |
| CA3159113A1 (en) | 2021-05-27 |
| EP4061427A1 (en) | 2022-09-28 |
| EP4061427A4 (en) | 2024-01-10 |
| CN119978146A (zh) | 2025-05-13 |
| JP2025102825A (ja) | 2025-07-08 |
| BR112022009864A2 (pt) | 2022-08-02 |
| WO2021102234A1 (en) | 2021-05-27 |
| KR20220116459A (ko) | 2022-08-23 |
| MX2022006188A (es) | 2022-08-22 |
| CO2022008507A2 (es) | 2022-07-08 |
| CN115023242B (zh) | 2025-03-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240100194A1 (en) | Adeno-associated viral vector variants | |
| Deverman et al. | Gene therapy for neurological disorders: progress and prospects | |
| IL291789A (en) | Adeno-associated virus (aav) systems for the treatment of genetic hearing loss | |
| US20240197920A1 (en) | Adeno-associated viral vectors for transduction of cochlea | |
| IL295542A (en) | Compositions and methods for inducible alternative splicing regulation of gene expression | |
| US20130281516A1 (en) | Multicistronic expression constructs | |
| WO2023220287A1 (en) | Adeno-associated viral vectors for targeting deep brain structures | |
| US20250312399A1 (en) | Adeno-associated viral vectors for targeting brain microvasculature | |
| RU2845941C1 (ru) | Варианты аденоассоциированного вирусного вектора | |
| JP2023540545A (ja) | 調節核酸配列 | |
| US20250269064A1 (en) | Human ependyma-specific promoter and uses thereof | |
| WO2025231387A1 (en) | Globus pallidus route of administration for deep brain gene therapies |